Tweet
Transplantation. 2012 Feb 28. [Epub ahead of print]
Deficient Long-Term Response to Pandemic Vaccine Results in An Insufficient Antibody Response to Seasonal Influenza Vaccination in Solid Organ Transplant Recipients.
Cordero E, Aydillo TA, Perez-Ordo?ez A, Torre-Cisneros J, Lara R, Segura C, Gentil MA, Gomez-Bravo MA, Lage E, Pachon J, Perez-Romero P.
Source
1 Instituto de Biomedicina de Sevilla (IBiS), University Hospital Virgen del Rocio/CSIC/University of Sevilla. Unit of Infectious Diseases, Microbiology and Preventive Medicine, Sevilla, Spain. 2 Clinic Unit of Infectious Diseases and Service of Cardiology, Maimonides Institute for Biomedical Research (IMIBIC) Reina Sofia University Hospital, University of C?rdoba (UCO), C?rdoba, Spain. 3 Service of Nephrology, Hospitales Universitarios Virgen del Roc?o, Sevilla, Spain. 4 Hepatobiliary and Pancreatic Surgery and Hepatic Transplant Unit, Hospitales Universitarios Virgen del Roc?o, Sevilla, Spain. 5 Service of Cardiology, Hospitales Universitarios Virgen del Roc?o, Sevilla, Spain.
Abstract
BACKGROUND:
Little is known about the long-term antibody response to the 2009-H1N1 vaccine in solid organ transplant recipients (SOTR) and its clinical repercussion on the efficacy of following 2010-2011 influenza vaccine.
METHODS:
We performed a multicenter prospective study in SOTR receiving one dose of the nonadjuvant 2010-2011 seasonal influenza vaccine and determined the immunological response at 5 weeks after vaccination.
RESULTS:
One hundred SOTR were included. Long-term antibody titers to the previous vaccine were only detected in one third of the patients. Patients with baseline titers had significantly higher seroprotection for the 2009-H1N1 strain (100% vs. 73%, relative risks [RR] 1.37, 95% confidence intervals [CI] 1.19-1.57; P=0.006), for H3N2 strain (100% vs. 62.2%, RR 1.61, 95% CI 1.36-1.90; P=0.005), and for B strain (100% vs. 69%; P=0.02). The seroconversion rate in patients with baseline titers was 90.9% vs. 73% (RR 2.97, 95% CI 0.75-11.74; P=0.07) for the 2009-H1N1 strain, 92.2% vs. 62.2% (RR 5.29, 95% CI 0.8-35.7; P=0.02) for the H3N2 strain, and 58.3% vs. 69% (P=0.45) for the B strain.
CONCLUSIONS:
SOTR response to the 2010-2011 influenza vaccine was not optimal. The response was related to baseline titers; however, most of the patients did not exhibit detectable antibodies at vaccination lacking long-term response. New strategies are necessary to improve vaccination efficacy.
PMID:
22377789
[PubMed - as supplied by publisher]
Deficient Long-Term Response to Pandemic Vaccine Results in An Insufficient Antibody Response to Seasonal Influenza Vaccination in Solid Organ Transplant Recipients.
Cordero E, Aydillo TA, Perez-Ordo?ez A, Torre-Cisneros J, Lara R, Segura C, Gentil MA, Gomez-Bravo MA, Lage E, Pachon J, Perez-Romero P.
Source
1 Instituto de Biomedicina de Sevilla (IBiS), University Hospital Virgen del Rocio/CSIC/University of Sevilla. Unit of Infectious Diseases, Microbiology and Preventive Medicine, Sevilla, Spain. 2 Clinic Unit of Infectious Diseases and Service of Cardiology, Maimonides Institute for Biomedical Research (IMIBIC) Reina Sofia University Hospital, University of C?rdoba (UCO), C?rdoba, Spain. 3 Service of Nephrology, Hospitales Universitarios Virgen del Roc?o, Sevilla, Spain. 4 Hepatobiliary and Pancreatic Surgery and Hepatic Transplant Unit, Hospitales Universitarios Virgen del Roc?o, Sevilla, Spain. 5 Service of Cardiology, Hospitales Universitarios Virgen del Roc?o, Sevilla, Spain.
Abstract
BACKGROUND:
Little is known about the long-term antibody response to the 2009-H1N1 vaccine in solid organ transplant recipients (SOTR) and its clinical repercussion on the efficacy of following 2010-2011 influenza vaccine.
METHODS:
We performed a multicenter prospective study in SOTR receiving one dose of the nonadjuvant 2010-2011 seasonal influenza vaccine and determined the immunological response at 5 weeks after vaccination.
RESULTS:
One hundred SOTR were included. Long-term antibody titers to the previous vaccine were only detected in one third of the patients. Patients with baseline titers had significantly higher seroprotection for the 2009-H1N1 strain (100% vs. 73%, relative risks [RR] 1.37, 95% confidence intervals [CI] 1.19-1.57; P=0.006), for H3N2 strain (100% vs. 62.2%, RR 1.61, 95% CI 1.36-1.90; P=0.005), and for B strain (100% vs. 69%; P=0.02). The seroconversion rate in patients with baseline titers was 90.9% vs. 73% (RR 2.97, 95% CI 0.75-11.74; P=0.07) for the 2009-H1N1 strain, 92.2% vs. 62.2% (RR 5.29, 95% CI 0.8-35.7; P=0.02) for the H3N2 strain, and 58.3% vs. 69% (P=0.45) for the B strain.
CONCLUSIONS:
SOTR response to the 2010-2011 influenza vaccine was not optimal. The response was related to baseline titers; however, most of the patients did not exhibit detectable antibodies at vaccination lacking long-term response. New strategies are necessary to improve vaccination efficacy.
PMID:
22377789
[PubMed - as supplied by publisher]
